Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population

International Journal of Urology

Volumn 10, Issue 5, 2003, Pages 261-266

  Suzuki, Kazuhiro ^a   Matsui, Hiroshi ^a   Ohtake, Nobuaki ^a   Nakata, Seiji ^a   Takei, Tomoyuki ^a   Koike, Hidekazu ^a   Nakazato, Haruki ^a   Okugi, Hironobu ^a   Hasumi, Masaru ^a   Fukabori, Yoshitatsu ^a   Kurokawa, Kohei ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Family history; Genetic polymorphism; Prostate cancer; Vitamin D receptor

Indexed keywords

GENOMIC DNA; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNIC GROUP; FAMILIAL CANCER; FAMILY HISTORY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RECEPTOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0038632320     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00617.x     Document Type: Article

References (25)

1. Corder EH, Guess HA, Hulka BS et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 1993; 2: 467-72.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1995; 10: 1307-11.
3. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998; 159: 2035-40.
4. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54: 805-10.
5. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer. 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.
6. Miller GJ, Stapleton GE, Ferrara JA et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1992; 52: 515-20.
7. Morrison NA, Qi JC, Tokita A et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-7.
8. Habuchi T, Suzuki T, Sasaki R et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000; 60: 305-8.
9. Hamasaki T, Inatomi H, Katoh K, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocrine J. 2001; 48: 543-9.
10. Furuya Y, Akakura K, Masai M, Ito H. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. Endocrine J. 1999; 46: 467-70.
11. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996; 56: 4108-10.
12. Correa-Cerro K, Berthon P, Haussler J et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum. Genet. 1999; 105: 281-7.
13. Ma J, Stampfer MJ, Gann PH et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomark. Prev. 1998; 7: 385-90.
14. Watanabe M, Fukutome K, Murata N et al. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res. 1999; 19: 4511-14.
15. Gsur A, Maderbacher S, Haidinger G et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002; 51: 30-4.
16. Blazer DG, Umbach DM, Bostick RM, Tayor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol. Carcinog. 2000; 27: 18-23.
17. Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-4.
18. Xu J, Meyers D, Freije D et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 1998; 20: 175-9.
19. Rebbeck TR, Walker AH, Zeigler-Johnson C et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet. 2000; 67: 1014-19.
20. Carpten J, Nupponen N, Isaacs S et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPCl. Nat. Genet. 2002; 30: 181-4.
21. Walsh PC & Partin AW. Family history facilitates the early diagnosis of prostate carcinoma. Cancer 1997; 80: 1871-4.
22. Grönberg H, Wiklund F, Damber JE. Age specific risks of familial prostate carcinoma. Cancer 1999; 86: 477-83.
23. Ingles SA, Coetzee GA, Ross RD et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 1998; 58: 1620-3.
24. Chokkalingam AP, McGlynn KA, Gao YT et al. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2001; 61: 4333-6.
25. Schatzl G, Gsur A, Bernhofer G et al. Association of vitamin D receptor and 17hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology 2001; 57: 567-72.